Cartesian Therapeutics says Descartes-08 retreatment cuts MG-ADL by 6.6 points at 12 months in myasthenia gravis study

• Cartesian Therapeutics released additional retreatment data for Descartes-08 in generalized myasthenia gravis, presented at the 2026 AANEM meeting.
• Retreated patients showed deep symptom improvement that held through 12 months, supporting repeat dosing when symptoms return.
• Safety remained consistent with earlier results, with no new concerns reported during retreatment.
• Phase 3 AURORA topline data are expected in 1Q27, setting up a planned mid-2027 BLA filing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cartesian Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290730PRIMZONEFULLFEED9835465) on September 29, 2026, and is solely responsible for the information contained therein.